The Role of Posture in Musculoskeletal Injury: Evaluation and Treatment Guidelines (Postural Adaptations With Sport, Occupation, and Aging)

2012 ◽  
pp. 1-28
Author(s):  
Janice K. Loudon
Keyword(s):  
Treatment Guidelines ◽  
Musculoskeletal Injury

scholarly journals Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review

Open Heart ◽  
2021 ◽  
Vol 8 (1) ◽  
pp. e001628
Author(s):  
Kamal Matli ◽  
Raymond Farah ◽  
Mario Maalouf ◽  
Nibal Chamoun ◽  
Christy Costanian ◽  
...  
Keyword(s):  
Treatment Guidelines ◽  
Anticoagulation Therapy ◽  
Antiplatelet Agents ◽  
Organ Damage ◽  
Multiple Organ ◽  
Rapid Review ◽  
Thromboembolic Events ◽  
Antithrombotic Agent ◽  
Heparin Resistance

Although primarily affecting the respiratory system, COVID-19 causes multiple organ damage. One of its grave consequences is a prothrombotic state that manifests as thrombotic, microthrombotic and thromboembolic events. Therefore, understanding the effect of antiplatelet and anticoagulation therapy in the context of COVID-19 treatment is important. The aim of this rapid review was to highlight the role of thrombosis in COVID-19 and to provide new insights on the use of antithrombotic therapy in its management. A rapid systematic review was performed using preferred reporting items for systematic reviews. Papers published in English on antithrombotic agent use and COVID-19 complications were eligible. Results showed that the use of anticoagulants increased survival and reduced thromboembolic events in patients. However, despite the use of anticoagulants, patients still suffered thrombotic events likely due to heparin resistance. Data on antiplatelet use in combination with anticoagulants in the setting of COVID-19 are quite scarce. Current side effects of anticoagulation therapy emphasise the need to update treatment guidelines. In this rapid review, we address a possible modulatory role of antiplatelet and anticoagulant combination against COVID-19 pathogenesis. This combination may be an effective form of adjuvant therapy against COVID-19 infection. However, further studies are needed to elucidate potential risks and benefits associated with this combination.

scholarly journals Evidence-Based Surgical Treatment Algorithm for Unstable Syndesmotic Injuries

2022 ◽  
Vol 11 (2) ◽  
pp. 331
Author(s):  
Markus Regauer ◽  
Gordon Mackay ◽  
Owen Nelson ◽  
Wolfgang Böcker ◽  
Christian Ehrnthaller
Keyword(s):  
Surgical Treatment ◽  
Systematic Reviews ◽  
Treatment Guidelines ◽  
Screw Fixation ◽  
External Rotation ◽  
Treatment Algorithm ◽  
Evidence Based ◽  
Posterior Malleolus ◽  
Anatomic Reduction

Background: Surgical treatment of unstable syndesmotic injuries is not trivial, and there are no generally accepted treatment guidelines. The most common controversies regarding surgical treatment are related to screw fixation versus dynamic fixation, the use of reduction clamps, open versus closed reduction, and the role of the posterior malleolus and of the anterior inferior tibiofibular ligament (AITFL). Our aim was to draw important conclusions from the pertinent literature concerning surgical treatment of unstable syndesmotic injuries, to transform these conclusions into surgical principles supported by the literature, and finally to fuse these principles into an evidence-based surgical treatment algorithm. Methods: PubMed, Embase, Google Scholar, The Cochrane Database of Systematic Reviews, and the reference lists of systematic reviews of relevant studies dealing with the surgical treatment of unstable syndesmotic injuries were searched independently by two reviewers using specific terms and limits. Surgical principles supported by the literature were fused into an evidence-based surgical treatment algorithm. Results: A total of 171 articles were included for further considerations. Among them, 47 articles concerned syndesmotic screw fixation and 41 flexible dynamic fixations of the syndesmosis. Twenty-five studies compared screw fixation with dynamic fixations, and seven out of these comparisons were randomized controlled trials. Nineteen articles addressed the posterior malleolus, 14 the role of the AITFL, and eight the use of reduction clamps. Anatomic reduction is crucial to prevent posttraumatic osteoarthritis. Therefore, flexible dynamic stabilization techniques should be preferred whenever possible. An unstable AITFL should be repaired and augmented, as it represents an important stabilizer of external rotation of the distal fibula. Conclusions: The current literature provides sufficient arguments for the development of an evidence-based surgical treatment algorithm for unstable syndesmotic injuries.

scholarly journals The Role of Prophetic Medicines in the Treatment of COVID-19

2021 ◽  
pp. 34-42
Author(s):  
SMH Kabir ◽  
AAhad M. Osman-Gani
Keyword(s):  
Treatment Guidelines ◽  
Nigella Sativa ◽  
Continuous Growth ◽  
Global Pandemic ◽  
Open Access Journals ◽  
Online Databases ◽  
Global Concern ◽  
Cross Reference ◽  
Natural Honey

Health safety is now a global concern. With the continuous growth of global pandemic in recent times caused by COVID-19 infectious disease, numerous remedies developed which were mostly supportive rather than curative. The objective of this study was to scrutinize reported literature on the inspiration of medical treatment based on Prophetic medicines in the fight against COVID-19. The inception of treatment guidelines using Prophetic medicines is the ideal combination of a specific arrangement of connections between science and Islam. A review of the literature has been conducted across online databases available by Medline, PubMed, Google Scholar, Science Direct, Directory of Open Access Journals (DOAJ) and Cross Reference, while searched to recognize articles associated with Prophetic medicines related to the treatment of COVID-19. Qualified studies addressed the treatment guidelines using Nigella Sativa, Anthemis Hyalina and Natural Honey were accounted. The findings revealed useful information that can be valuable to researchers working on the treatment of corona virus. Alternatively, this paper is one of the few systematic reviews on the treatment guidelines based on prophetic medicines in the fight against COVID-19.

scholarly journals Venous Thromboembolism in COVID-19

2020 ◽  
Vol 120 (12) ◽  
pp. 1642-1653 ◽  
Author(s):  
Sam Schulman ◽  
Yu Hu ◽  
Stavros Konstantinides
Keyword(s):  
Venous Thromboembolism ◽  
Potential Role ◽  
Treatment Guidelines ◽  
Swine Flu ◽  
Thrombolytic Treatment ◽  
Medically Ill ◽  
Risk Assessment Models ◽  
Consensus Statements ◽  
Medically Ill Patients

AbstractThe coronavirus disease 2019 (COVID-19) is our latest pandemic, preceded by the H1N1 swine flu in 2009, which lasted approximately 19 months. One of the special characteristics of COVID-19 is the propensity to cause venous thromboembolism (VTE). Thromboinflammation seems to play a prominent role in the pathogenesis. We will here review some mechanisms in the pathogenesis and discuss some hematological biomarkers, and also whether they serve as useful risk factors for VTE. The role of general risk assessment models for medically ill patients specifically in COVID-19 is appraised. The type of prophylaxis and particularly whether standard or augmented doses of chemoprophylaxis should be used is reviewed based on available evidence. We are also comparing recommendations from 10 different guidance or position/consensus statements. Treatment recommendations for patients with COVID-19 and pulmonary embolism are discussed with current general treatment guidelines as reference. Specifics for patients with COVID-19 are pointed out and the potential role of thrombolytic treatment is explored.

Do Benzodiazepines Still Deserve a Major Role in The Treatment of Psychiatric Disorders? A Critical Reappraisal

2013 ◽  
Vol 28 (1) ◽  
pp. 7-20 ◽  
Author(s):  
B. Dell’osso ◽  
M. Lader
Keyword(s):  
Psychiatric Disorders ◽  
Critical Appraisal ◽  
Randomized Clinical Trials ◽  
Treatment Guidelines ◽  
Scientific Evidence ◽  
Family Physicians ◽  
Therapeutic Index ◽  
The Elderly ◽  
High Therapeutic Index

AbstractDiscovered in the late 1950s by Leo Sternbach, the first benzodiazepine (BZD) chlordiazepoxide was followed by several congeners, which rapidly constituted one of the largest and most widely prescribed classes of psychotropic compounds. After 50 years, BZDs are still routinely utilized not only in psychiatry but, more generally, in the whole of medicine. Despite their high therapeutic index which makes BZDs safer than other compounds like barbiturates, as well as their rapidity of onset, psychiatrists and family physicians are well aware about the controversy that surrounds the wide use – often not adequately based on scientific evidence – of BZDs in many psychiatric disorders. In this overview of international treatment guidelines, systematic reviews and randomized clinical trials, the aim was to provide a critical appraisal of the current use and role of BZDs in psychiatric disorders and their disadvantages, with specific emphasis on anxiety and affective disorders, sleep disorders, alcohol withdrawal, violent and aggressive behaviours in psychoses, and neuroleptic-induced disorders. In addition, specific emphasis has been given to the extent of usage of BZDs and its appropriateness through the assessment of available international surveys. Finally, the entire spectrum of BZD-related adverse effects including psychomotor effects, use in the elderly, paradoxical reactions, tolerance and rebound, teratologic risk, dependence, withdrawal and abuse issues was examined in detail.

scholarly journals Patient Assessment: Clinical Presentation, Imaging Diagnosis, Risk Stratification, and the Role of Pulmonary Embolism Response Team

2018 ◽  
Vol 35 (02) ◽  
pp. 116-121 ◽  
Author(s):  
Tamir Friedman ◽  
Keith Quencer ◽  
David Madoff ◽  
Ronald Winokur
Keyword(s):  
Pulmonary Embolism ◽  
Clinical Presentation ◽  
Treatment Guidelines ◽  
The United States ◽  
Imaging Diagnosis ◽  
Patient Assessment ◽  
Timely Manner ◽  
Response Team ◽  
Hospital Deaths

AbstractPulmonary embolism (PE) is currently the third leading cause of death and moreover is likely underdiagnosed. PE remains the most common preventable cause of hospital deaths in the United States, which may be attributable to its diagnostic challenges. Although difficult to diagnose, patient mortality rates are time-dependent, and thus, the suspicion and diagnosis of PE in a timely manner is imperative. Diagnosis based on several criteria which may dictate imaging workup as well as laboratory tests and clinical parameters are discussed. The evolution of treatment guidelines via various clinical trials and recommendations is outlined, setting the stage for the use of fibrinolytics, whether systemic or catheter directed. Treatment, including fibrinolytics, is predicated on patient triage into three large categories—massive, submassive, or low-risk PE. Additionally, a relatively new concept of a multidisciplinary team composed of several subspecialty experts known as the PE response team (PERT) is discussed. PERT's timely and unified recommendations have been shown to optimize care and decrease mortality while tailoring treatment to each individual afflicted by PE.

Sign in / Sign up

Export Citation Format

Share Document